Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
NCT02491099Phase 2Recruiting
- Sponsor
- Yale University
- Start
- Jun 2015
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in uterine serous carcinoma (USC), sponsored by Yale University. Started Jun 2015; status: recruiting.
02
Drugs
afatinib
03
Conditions
uterine serous carcinoma (USC)
Beyond the preview
Go deeper on NCT02491099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02491099.